Segall Bryant & Hamill LLC Sells 2,073 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Segall Bryant & Hamill LLC reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 353,103 shares of the biopharmaceutical company’s stock after selling 2,073 shares during the period. Segall Bryant & Hamill LLC owned about 0.28% of Halozyme Therapeutics worth $16,882,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth $69,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth $1,886,000. Retirement Systems of Alabama raised its holdings in shares of Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after purchasing an additional 74,173 shares during the last quarter. Shaker Investments LLC OH lifted its position in shares of Halozyme Therapeutics by 12.3% during the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company’s stock valued at $3,601,000 after purchasing an additional 8,249 shares in the last quarter. Finally, Foster & Motley Inc. boosted its holdings in Halozyme Therapeutics by 118.6% during the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after purchasing an additional 12,630 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 1.3 %

Shares of Halozyme Therapeutics stock opened at $64.84 on Wednesday. The stock has a market capitalization of $8.01 billion, a P/E ratio of 18.90, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $66.00. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock’s 50-day simple moving average is $58.39 and its 200 day simple moving average is $54.68.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on HALO. Benchmark reiterated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock valued at $1,754,451 over the last three months. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.